-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CompilationFan Dongdong
Several vaccine researchers at GlaxoSmithKline have opted to leave in the past year, but the company has poached heavyweights from Pfizer to get its vaccine business back on track
During his tenure at Pfizer, he worked on Pfizer and BioNTech's well-known COVID-19 vaccine Comirnaty, as well as the experimental respiratory syncytial virus vaccine and its early RNA vaccine against influenza
In fact, Pfizer and GlaxoSmithKline are going head-to-head in the RSV vaccine race, with both releasing positive data this year, and the companies competing to see who can reach the trial endpoint first
In July of this year, GlaxoSmithKline disclosed that it had terminated a respiratory complex virus (RSV) pediatric vaccine candidate (viral vector) GSK3389245A in phase 2 clinical development, because the evaluation showed that the efficacy of the vaccine in protecting children was unlikely reach the target value
Dormitzer's superior, GlaxoSmithKline Chief Safety Officer and R&D President Dr.
This follows a small exodus from GSK's vaccine talent pool, including its former head of vaccine research, Dr.
Analysts believe Dormitzer's entry will hopefully help stabilize the ship
Reference source: GlaxoSmithKline poaches Pfizer vax leader Dormitzer after hemorrhaging vaccine R&D talent
